ZLAB — Zai Lab Ltd

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1704292 · China
Last close
$24.98
Market Cap
$2.80B
52W High
$34.72
52W Low
$15.96
ADV30
969,583
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 106,311,000 58,149,000 -76,489,000 -50,825,000 1,074,793,000 607,522,000 467,756,000
Mar 2026 99,611,000 61,276,000 -69,279,000 -51,016,000 1,095,737,000 651,316,000 433,756,000
Dec 2025 127,597,000 65,266,000 -68,264,000 -50,409,000 1,172,384,000 679,573,000 456,884,000
Sep 2025 116,095,000 69,212,000 -47,968,000 -35,963,000 1,158,940,000 717,155,000 398,995,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-133,384,000
Investing CF
$-39,050,000
Financing CF
$44,641,000
CapEx
$-29,134,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.80
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,730,461,000
Inventory
$90,890,000
Receivables
$72,990,000
ST Investments
$10,000,000
EBIT TTM
$-184,737,000
Pretax Income TTM
$-190,722,000
Interest Exp TTM
$5,985,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$449,614,016
EBITDA
$-248,168,000
Free Cash Flow
$-83,963,752
Enterprise Value
$2,347,160,832
Total Cash
$617,521,984
Total Debt
$254,576,000
Shares Out
112,266,228
Trailing EPS
$-1.70
Book Value
$5.41
ROE
-26.9%
ROA
-14.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 460,156,000 -223,572,000 -175,537,000 1,172,384,000 456,884,000 715,500,000 -150,789,000
Dec 2024 398,988,000 -273,947,000 -257,103,000 1,185,753,000 344,855,000 840,898,000 -214,869,000
Dec 2023 266,719,000 -374,140,000 -334,620,000 1,036,295,000 240,177,000 796,118,000 -198,178,000
Dec 2022 215,040,000 -392,886,000 -443,286,000 1,220,140,000 174,545,000 1,045,595,000 -367,642,000

TTM Snapshot

Revenues TTM
$102,265,000
NetIncome TTM
$-41,671,000
OpCashFlow TTM
$0
Assets (Latest)
$1,185,753,000
Forward EPS
$-2.11

Max Pain — expiry 2027-01-15

max pain strike: $25.00 · spot: $26.12 · call oi: 3,724 · put oi: 2,740
Expected Move to 2027-01-15: ±$8.10 (31.01%) — implied range $18.02 – $34.22 · ATM straddle on $25.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PGEN PRECIGEN, INC. $2.77B $7.75 —
QURE uniQure N.V. $2.65B $38.23 —
NAMS NewAmsterdam Pharma Co N.V. $2.64B $22.58 —
DYN Dyne Therapeutics, Inc. $2.99B $16.03 —
MBX MBX Biosciences, Inc. $2.58B $53.63 —

News headlines (Yahoo Finance, 1h cache)

Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks
2026-09-06 18:11 · Yahoo
Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics
2026-08-20 15:30 · Yahoo
Coultreon Biopharma Appoints Prista Charuworn, MD as Chief Medical Officer
2026-08-18 07:00 · Yahoo
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript
2026-08-13 13:58 · Yahoo
Big Pharma Is Pouring Billions Into China’s Biotechs
2026-09-14 07:59 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up 2% for Week
2026-08-28 14:37 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading
2026-08-13 14:44 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
2026-09-24 14:34 · Yahoo
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-24 12:16 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-09-02 14:39 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.